LB2505 / Legend Biotech - LARVOL DELTA

...planned second-half 2026 U.S. IND, LB2505 dosing and additional TaVec programs. (Investing.com)

IND • Immunology • Myasthenia Gravis • Systemic Lupus Erythematosus

A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Autoimmune Diseases (clinicaltrials.gov) - P1 | N=44 | Not yet recruiting | Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

New P1 trial • CNS Disorders • Immunology • Inflammation • Inflammatory Arthritis • Lupus • Multiple Sclerosis • Myasthenia Gravis • Systemic Lupus Erythematosus